Literature DB >> 25263848

p40 is a more specific marker than p63 for cutaneous poorly differentiated squamous cell carcinoma.

Ahmed K Alomari1, Earl J Glusac, Jennifer M McNiff.   

Abstract

BACKGROUND: Poorly differentiated squamous cell carcinoma (SCC) of the skin may pose a diagnostic challenge for pathologists. p40 is a recently introduced antibody that recognizes specific p63 protein isoforms and has shown superior results labeling non-cutaneous SCC. We hypothesize that p40 may improve diagnostic accuracy of poorly differentiated SCC.
METHODS: Twelve cases of poorly differentiated SCC were stained with p63, p40 and cytokeratin MNF116. Control cases included nine atypical fibroxanthoma (AFX), five cutaneous leiomyosarcoma (LMS) and three giant cell tumors of soft tissue (GCTST).
RESULTS: All 12 cases labeled with p63 and p40 and 11/12 were positive with MNF116. Whereas p40 labeled fewer cells, it showed exclusive nuclear staining, with no staining of cytoplasm or of background cells, in contrast to p63. Six of nine AFX and 2 of 3 GCTST showed scattered nuclear staining with p63 but were negative with p40. Additionally, one LMS showed focal staining with MNF116 but was negative with p40.
CONCLUSION: For the diagnosis of cutaneous poorly differentiated SCC, p40 appears equally sensitive to MNF116 and p63. While labeling fewer cells, p40 labels without confounding staining of tumor cytoplasm or background cells. More importantly, p40 appears to be more specific for SCC than p63 and MNF116, each of which occasionally labels non-squamous tumors.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  cutaneous squamous cell carcinoma; immunocytochemistry; immunohistochemistry; p63; squamous cell carcinomas

Mesh:

Substances:

Year:  2014        PMID: 25263848     DOI: 10.1111/cup.12388

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  8 in total

1.  Establishment of a Clinic-based Biorepository.

Authors:  Sarah E Belden; Chandana K Uppalapati; Agnes S Pascual; McKale R Montgomery; Kathryn J Leyva; Elizabeth E Hull; Richard L Averitte
Journal:  J Vis Exp       Date:  2017-05-29       Impact factor: 1.355

Review 2.  Squamous cell carcinoma arising in an epidermal inclusion cyst.

Authors:  Suzanne Alkul; Christopher N Nguyen; Nisha S Ramani; Mahmud Alkul; Ida Orengo; Ikue Shimizu; Bhuvaneswari Krishnan
Journal:  Proc (Bayl Univ Med Cent)       Date:  2022-05-23

3.  Cutaneous spindle cell carcinoma misdiagnosed as atypical fibroxanthoma based on immunohistochemical stains.

Authors:  Anastasia Benoit; Joshua Wisell; Mariah Brown
Journal:  JAAD Case Rep       Date:  2015-11-02

4.  Metastatic Primary Gastric Squamous Cell Carcinoma: An Uncommon Presentation of a Rare Malignancy.

Authors:  Michael Beattie; Ramy Mansour; Derek Thigpin; Carolyn Haus
Journal:  Case Rep Gastrointest Med       Date:  2019-10-07

Review 5.  p63 Is a Promising Marker in the Diagnosis of Unusual Skin Cancer.

Authors:  Artem Smirnov; Lucia Anemona; Flavia Novelli; Cristina M Piro; Margherita Annicchiarico-Petruzzelli; Gerry Melino; Eleonora Candi
Journal:  Int J Mol Sci       Date:  2019-11-17       Impact factor: 5.923

Review 6.  Role of immunohistochemistry in the diagnosis and staging of cutaneous squamous-cell carcinomas (Review).

Authors:  Elena Bălășescu; Andreea-Cristina Gheorghe; Andreea Moroianu; Gabriela Turcu; Alice Brînzea; Mihaela Antohe; Anastasia Hodorogea; Lorena Manea; Mihaela Balaban; Răzvan Andrei; Ionela Hulea; Cristiana Gabriela Popp; Luciana Nichita; Mirela Daniela Cioplea; Sabina Andrada Zurac; Daniela Adriana Ion; Roxana Ioana Nedelcu
Journal:  Exp Ther Med       Date:  2022-04-11       Impact factor: 2.447

7.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer.

Authors:  Ann W Silk; Christopher A Barker; Shailender Bhatia; Kathryn B Bollin; Sunandana Chandra; Zeynep Eroglu; Brian R Gastman; Kari L Kendra; Harriet Kluger; Evan J Lipson; Kathleen Madden; David M Miller; Paul Nghiem; Anna C Pavlick; Igor Puzanov; Guilherme Rabinowits; Emily S Ruiz; Vernon K Sondak; Edward A Tavss; Michael T Tetzlaff; Isaac Brownell
Journal:  J Immunother Cancer       Date:  2022-07       Impact factor: 12.469

8.  CD109 is a novel marker for squamous cell/adenosquamous carcinomas of the gallbladder.

Authors:  Fengyun Dong; Chuanfeng Lu; Xiaocui Chen; Yuan Guo; Ju Liu
Journal:  Diagn Pathol       Date:  2015-08-07       Impact factor: 2.644

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.